Archive · 29 Jul 2025
Torrent Pharma Shares Hit 52-Week High After Q1 Results
Torrent Pharma, a pharmaceutical company, saw its stock price go up to its highest point in a year after reporting good financial results for the first three months of the fiscal year.
The company made a profit of ₹548 crore, which is 20% more than last year.
Many financial analysts think the stock is a good buy and have set higher prices for it.
Although the company is doing well, some analysts are slightly concerned about things like how much the stock is worth compared to its potential for future earnings.
Torrent Pharma's shares reached a 52-week high after Q1FY26 results.
Net profit increased by 20% year-over-year to ₹548 crore.
Multiple brokerages increased target prices and maintained positive ratings.
Citi and Nuvama retained 'Buy' ratings; Elara upgraded to 'Accumulate'.
Brokerage views varied, with some citing market risks and valuation concerns.
- Who
- Torrent Pharmaceuticals and various brokerages.
- What
- Torrent Pharma's shares hit a 52-week high following Q1 results.
- When
- After Q1FY26 results were released.
- Where
- BSE
- Why
- Due to positive Q1FY26 financial results and optimistic analyst views.
Market Optimism
Analyst Concerns
Valuation
Market Optimism
Positive Q1 Results Driving Growth.
Analyst Concerns
Stock is Priced to Perfection with Slowdown Risk.
- Stock Performance
- 52-week high
- Net Profit (Q1FY26)
- ₹548 crore
- Profit Growth (YoY)
- 20%
- Citi Target Price
- ₹4,380
- Nuvama Target Price
- ₹4,180
